What is Wedbush’s Forecast for DAWN Q1 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Wedbush reduced their Q1 2025 EPS estimates for shares of Day One Biopharmaceuticals in a research report issued to clients and investors on Wednesday, February 26th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.43) for the quarter, down from their previous estimate of ($0.29). Wedbush currently has a “Outperform” rating and a $32.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.41) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at $0.21 EPS and FY2028 earnings at $1.24 EPS.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright decreased their target price on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Wednesday. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Bank of America decreased their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $34.86.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock opened at $9.06 on Friday. The stock has a market cap of $913.66 million, a P/E ratio of -8.80 and a beta of -1.46. The firm’s fifty day moving average price is $12.16 and its 200-day moving average price is $13.38. Day One Biopharmaceuticals has a fifty-two week low of $9.02 and a fifty-two week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to analysts’ expectations of $27.11 million.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of large investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Day One Biopharmaceuticals by 15.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 75,579 shares of the company’s stock valued at $958,000 after purchasing an additional 10,386 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $380,000. Stonepine Capital Management LLC boosted its stake in shares of Day One Biopharmaceuticals by 14.3% during the 4th quarter. Stonepine Capital Management LLC now owns 235,000 shares of the company’s stock valued at $2,977,000 after purchasing an additional 29,325 shares in the last quarter. Finally, Tema Etfs LLC bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $1,087,000. Institutional investors own 87.95% of the company’s stock.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total value of $399,300.00. Following the transaction, the insider now owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. The trade was a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares in the company, valued at $1,531,059.40. The trade was a 8.60 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,064 shares of company stock worth $651,225. 8.40% of the stock is currently owned by company insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.